drugset / Trial / NCT06389955
Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654
RandomizedCrossoverOpen-labelOther
Summary
This study comprised of 2 parts, Part A and Part B. Part B will only be conducted if the relative bioavailability of the tablet formulation was at least 70% of the capsule formulation.
Timeline
- Start
- 2023-05-22
- Primary completion
- 2023-08-01
- Completion
- 2023-08-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NUVISERTIB | Small molecule | 480 mg | Oral |
Indications
No indication recorded.